AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

About this update from An2 Therapeutics, Inc.

MENLO PARK, Calif., March 03, 2025 --( BUSINESS WIRE )--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference. Details of the event are as follows: Leerink Partners Global Healthcare Conference Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, March 12, 2025 at 2:20 pm ET, and members of management will be available for 1X1 meetings. A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com . An archived replay will be available for at least 30 days following the presentation. About AN2 Therapeutics, Inc. AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. For more information, please visit our website at www.an2therapeutics.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20250303805852/en/ Contacts COMPANY CONTACT: Lucy O. Day Chief Financial Officer [email protected] INVESTOR AND MEDIA CONTACT: Anne Bowdidge [email protected]

View stock analysis, news, and events for An2 Therapeutics, Inc.